Skip to Content
Merck

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus.

Scientific reports (2013-08-27)
Hirotaka Ebina, Naoko Misawa, Yuka Kanemura, Yoshio Koyanagi
ABSTRACT

Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
CRISPR/Cas9 Products and Services, Design and order CRISPR gRNA, Cas9, screening libraries, controls and companion products. Formats include plant, lentivirus, IVT-RNA, plasmid, synthetic, and protein.